Therapeutic manipulation of the immune system against cancer has revolutionized cancer treatment. Given that the immune system is evolutionarily trained to respond to nano-sized objects, these structures can be successfully recognized by cells of the innate and adaptive immune system. The use of nanoparticles has the potential to modulate cancer cells and contribute to anticancer immunotherapy efficacy. In addition, there is ongoing research focusing on the use of nanoparticles as vaccines or immunomodulatory agents, as nanoparticles are well suited to these applications.

As the benefits of nanomedicine for cancer therapy have been realized, such nanotechnologies have been incorporated into larger-scale systems. However, although numerous preclinical studies have been published with successful preliminary results, there are challenges that must be overcome before these promising nano-systems can be adopted in clinical practice as a safe option for cancer patients. Such challenges include low levels of tumor targeting, complex mechanism of therapeutic efficiency and limited commercial success.

This Special Issue aims to bring together advances in novel approaches for nanomedicine-based cancer immunotherapy. This Special Issue will collate research on the latest advances on the use of nanoparticles for drug delivery in combination with immunotherapy for the treatment of cancers. We particularly welcome research focusing on novel nanomaterials that selectively target immune cell populations as well as research focusing on targeted delivery of immunotherapeutics to solid tumors. We invite submissions of original research and review articles.

Potential topics include but are not limited to the following:

• Novel emerging nanomedicines for effective cancer immunotherapy
• Cancer nanomedicine to enhance tumor delivery and immunotherapy
• Nanoparticle design strategies for effective cancer immunotherapy
• Light-based (photothermal therapy (PPT), photodynamic (PDT) and chemodynamic therapies with nanoparticles
• Modulation of tumor microenvironment induced by nanoparticles
• Nanoparticle-sensitized immune responses to chemoradiotherapy
• Pharmacokinetics of novel nanomedicines combined with immunotherapy
• Nanoparticle systems to reduce systemic toxicity in cancer treatment
• Nanoparticles as imaging tracers in the monitoring of response to immunotherapy
• Challenges of nanomedicines in clinical application
• Sustained-release particles for use in targeted immunotherapy of cancer